Search

Displaying results 7651 - 7660 of 10000 in total
  1. Drug

    Remacemide

    go.drugbank.com/drugs/DB06458
    Experimental

    Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    Mitumomab

    go.drugbank.com/drugs/DB06462
    Experimental

    Mitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.

  3. Drug

    IR502

    go.drugbank.com/drugs/DB06463
    Experimental

    IR502 (Zorcell) is a potential treatment for psoriasis.

  4. Drug

    Sibrotuzumab

    go.drugbank.com/drugs/DB06474
    Investigational

    Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

  5. Drug

    Propentofylline

    go.drugbank.com/drugs/DB06479
    Experimental

    Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 Substrates
  6. Drug

    Ropidoxuridine

    go.drugbank.com/drugs/DB06485
    Investigational

    Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODOPYRIMIDIN-2(1H)-ONE, 2(1H)-PYRIMIDINONE, 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODO-
  7. Drug

    Liatermin

    go.drugbank.com/drugs/DB06489
    Investigational

    Synonyms: r-metHuGDNF
  8. Drug

    Sufugolix

    go.drugbank.com/drugs/DB06494
    Experimental

  9. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring
  10. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring